In the United States, the number of people currently living with a cancer diagnosis is at 14.5 million, while the number of cancer survivors is projected to reach 19 million by 2024. While these numbers are a strong testament to the progress and evolution of cancer treatments, many cancer survivors demonstrate increased rates of cardiovascular disease: posing questions surrounding cardiovascular safety of anticancer treatments. It is now a widely accepted fact that cardiovascular toxicity is a consequence of cancer therapies; the risk of adverse effects increases among patients with underlying cardiometabolic risk factors, including coronary disease, type 2 diabetes, dyslipidemia, and hypertension. The field of cardio-oncology is a rapidly evolving sector aimed at understanding the precise adverse cardiovascular effects of cancer treatments, in addition to the well-documented cardiotoxicity resulting from anthracycline treatment and other novel anticancer treatments.
To help clinicians in cardio-oncology navigate the challenges to optimizing care, Cardiometabolic Health Congress (CMHC) and the American Heart Association (AHA) have collaborated on a new workshop: CMHC-AHA Cardio-Oncology Workshop: Exploring the Frontiers of Care. This workshop serves as an educational opportunity, designed to increase awareness and engagement in the dynamic therapeutic area of cardio-oncology. We invite you to join leading experts in the field as they present the latest guidelines, prevention efforts, and treatment strategies regarding the adverse cardiovascular events of cancer treatments, through thought provoking, interactive, and innovative education.